

# GRANTS AND CONTRACTS

2016

**Fitzpatrick LR.** NIH Phase 2 SBIR grant to Visionary Pharmaceuticals. PI on subcontract (\$5,995). Colonic Histology Evaluations Related to the Effects of ROR- $\gamma$  T Inhibitors on Mice with Innate Immune Colitis. (**Award occurred in February of 2016**).

Fitzpatrick LR. NIH Phase 2 SBIR grant to Visionary Pharmaceuticals. PI on subcontract ((\$15,455). Ex Vivo Evaluations with Visionary ROR-Gamma T Inhibitors Using a Murine Model of Inflammatory Bowel Disease. (**Award occurred in July of 2016**).

**Phuong O.** Merck Sharp & Dohme CORE proposal (\$20,000). PI: Hospitalization for Heart Failure (HHF) Risks of Various DPP-4 Inhibitors. (Submitted in March of 2016).

**Vinall R.** NIH R15 (\$300,000 direct costs). PI: Role of the AR-ErbB3-Nrdp1 axis in mediating prostate cancer health disparities. Grant was submitted in 2015. (**Award Occurred in July of 2016**)

**Vinall R.** NIH P20 (\$708,932). PI: 1/2 Pharmacists and Cancer researchers Together: the CNUCOP-UCDCCC PACT. (Submitted in March of 2016).